Implication of Complement System and its Regulators in Alzheimer’s Disease

Alzheimer’s disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million people worldwide. A number of different risk factors have been implicated in AD, however, neuritic (amyloid) plaques are considered as one of the defining risk factors and pathological hallmarks of the disease. Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains. They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimer's dementia. This review emphasizes on the dual key roles of complement system and complement regulators (CRegs) in disease pathology and progression. The particular focus of this review is on currently evolving strategies for design of complement inhibitors that might aid therapy by restoring the fine balance between activated components of complement system, thus improving the cognitive performance of patients. This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of AD.

• Publication year

  2009

• Venue

  Current Neuropharmacology

• Publication date

  2009-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157015909787602805PMID 19721814PMCID 2724661
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells.

  2008cited by this paper
• Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.

  2008cited by this paper
• Regulation of betaAPP and PrPc cleavage by alpha-secretase: mechanistic and therapeutic perspectives.

  2008cited by this paper
• Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

  2008cited by this paper
• Regulation of βAPP and PrPc Cleavage by α-Secretase: Mechanistic and Therapeutic Perspectives

  2008cited by this paper
• Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice

  2008cited by this paper
• Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins.

  2007cited by this paper
• New perspectives on mannan-binding lectin-mediated complement activation.

  2007cited by this paper
• Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis.

  2007cited by this paper
• CD59, a Complement Regulatory Protein, Controls Choroidal Neovascularization in a Mouse Model of Wet-Type Age-Related Macular Degeneration1

  2007cited by this paper
• Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database

  2007cited by this paper
• Complement component C1q inhibits β‐amyloid‐ and serum amyloid P‐induced neurotoxicity via caspase‐ and calpain‐independent mechanisms

  2007cited by this paper
• Expression of complement regulators and receptors on human NT2-N neurons--effect of hypoxia and reoxygenation.

  2007cited by this paper
• Beneficial Effects of Complement Inhibition With Soluble Complement Receptor 1 (TP10) During Cardiac Surgery: Is There a Gender Difference?

  2007cited by this paper
• p53 regulates cellular resistance to complement lysis through enhanced expression of CD59.

  2006cited by this paper
• Cerebrolysin decreases amyloid‐β production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease

  2006cited by this paper
• Current Pharmacotherapy for Alzheimer ’ s Disease

  2006cited by this paper
• Current pharmacotherapy for Alzheimer's disease.

  2006cited by this paper
• Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis.

  2006cited by this paper
• Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.

  2006cited by this paper
• Holding T cells in check--a new role for complement regulators?

  2006cited by this paper
• Glycosaminoglycans inhibit neurodegenerative effects of serum amyloid P component in vitro.

  2005cited by this paper
• World Health Organization, Department of essential drugs and medicines policy

  2005cited by this paper
• Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer

  2004cited by this paper
• Soluble Human Complement Receptor 1 Limits Ischemic Damage in Cardiac Surgery Patients at High Risk Requiring Cardiopulmonary Bypass

  2004cited by this paper
• Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.

  2003cited by this paper
• Complement therapeutics; history and current progress.

  2003cited by this paper
• Modular Organization of the Carboxyl-Terminal, Globular Head Region of Human C1q A, B, and C Chains1

  2003influential reference
• Generation of Anti-complement “Prodrugs”

  2003cited by this paper
• Risk Factors for Alzheimer’s Disease: Role of Multiple Antioxidants, Non-Steroidal Anti-inflammatory and Cholinergic Agents Alone or in Combination in Prevention and Treatment

  2002cited by this paper
• Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice

  2002influential reference
• Eculizumab (Alexion).

  2002cited by this paper
• Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.

  2002cited by this paper
• Coupling complement regulators to immunoglobulin domains generates effective anti‐complement reagents with extended half‐life in vivo

  2002cited by this paper
• Complement. First of two parts.

  2001cited by this paper
• Membrane-targeted complement inhibitors.

  2001cited by this paper
• Activation of complement and contact system in Alzheimer's disease.

  2001cited by this paper
• Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid ß-protein

  2001cited by this paper
• Sublytic C5b‐9‐stimulated Schwann cell survival through PI 3‐kinase‐mediated phosphorylation of BAD

  2001cited by this paper
• Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy

  2000cited by this paper
• Deficiency of Complement Defense Protein CD59 May Contribute to Neurodegeneration in Alzheimer's Disease

  2000cited by this paper
• Selective and Protracted Apoptosis in Human Primary Neurons Microinjected with Active Caspase-3, -6, -7, and -8

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000cited by this paper
• Alzheimer disease and neuroinflammation.

  2000cited by this paper
• The role of complement in Alzheimer's disease pathology.

  2000cited by this paper
• Targeting of functional antibody-CD59 fusion proteins to a cell surface.

  1999cited by this paper
• Complement‐derived anaphylatoxin C5a protects against glutamate‐mediated neurotoxicity

  1999cited by this paper
• Up-regulated production and activation of the complement system in Alzheimer's disease brain.

  1999cited by this paper
• Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation.

  1999cited by this paper
• Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease.

  1999cited by this paper
• Translating cell biology into therapeutic advances in Alzheimer's disease

  1999cited by this paper
• Complement C1-inhibitor expression in Alzheimer’s disease

  1998cited by this paper
• Mannan‐binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease

  1998cited by this paper
• Complement-dependent Proinflammatory Properties of the Alzheimer's Disease β-Peptide

  1998influential reference
• Extrahepatic complement biosynthesis: where, when and why?

  1997cited by this paper
• Complement‐regulatory proteins in ovarian malignancies

  1997cited by this paper
• Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation.

  1996cited by this paper
• Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system.

  1996influential reference
• Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly.

  1995cited by this paper
• Nonsteroidal anti-inflammatory drugs in Alzheimer's disease

  1995cited by this paper
• Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines.

  1995cited by this paper
• Complement biosynthesis in the central nervous system.

  1995cited by this paper
• The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases.

  1995cited by this paper
• The expression of CD59 in normal human nervous tissue.

  1994cited by this paper
• Clusterin (SGP‐2): A multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain

  1994cited by this paper
• Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus.

  1992cited by this paper
• Expression of complement components of the alternative pathway by glioma cell lines.

  1992cited by this paper
• Association of amyloid P component with complement proteins in neurologically diseased brain tissue.

  1991cited by this paper
• Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.

  1990cited by this paper
• CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells

  1989cited by this paper
• Local immunoglobulin synthesis and blood-brain barrier assessment in subacute sclerosing panencephalitis.

  1985cited by this paper

• SEZ6L2 Loss Disrupts Motor Coordination, Cognitive Function, and Synaptic Connectivity

  2026cites this paper
• Factor H’s Control of Complement Activation Emerges as a Significant and Promising Therapeutic Target for Alzheimer’s Disease Treatment

  2024cites this paper
• Plant derived bioactive compounds for the treatment of neurodegeneration and neuroimmune disorders associated with the complement system

  2024cites this paper
• Cholesterol and Lipid Rafts in the Biogenesis of Amyloid-β Protein and Alzheimer's Disease.

  2024cites this paper
• The complement system in neurodegenerative and inflammatory diseases of the central nervous system

  2024cites this paper
• Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease

  2024cites this paper
• Anesthesia-mediated neuroinflammatory sequelae in post operative cognitive dysfunction: mechanisms and therapeutic implications

  2024cites this paper
• Influence of Alzheimer's Disease Related Neuropathology on Local Microenvironment Gene Expression in the Human Inferior Temporal Cortex

  2023cites this paper
• The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics.

  2023cites this paper
• ALZHEİMER HASTALIĞINDA KOMPLEMAN SİSTEMİN ROLÜ

  2023cites this paper
• Complement system biomarkers in fi rst episode psychosis

  2023cites this paper
• Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects

  2023cites this paper
• Evaluation of the effects of herpes simplex glycoprotein B on complement system and cytokines in in vitro models of Alzheimer's disease

  2023cites this paper
• The Specific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer’s Disease

  2022cites this paper
• Mining High-Level Imaging Genetic Associations via Clustering AD Candidate Variants with Similar Brain Association Patterns

  2022cites this paper
• The role of the complement system in Multiple Sclerosis: A review

  2022cites this paper
• Multi‐Omics‐Based Autophagy‐Related Untypical Subtypes in Patients with Cerebral Amyloid Pathology

  2022cites this paper
• Contribution of proteases to the hallmarks of aging and to age‐related neurodegeneration

  2022cites this paper
• Plasma protein biomarker model for screening Alzheimer disease using multiple reaction monitoring-mass spectrometry

  2022cites this paper
• Proteins in the pathway from high red blood cell width distribution to all-cause mortality

  2022cites this paper
• Interaction Between the Complement System and Infectious Agents – A Potential Mechanistic Link to Neurodegeneration and Dementia

  2021influential citation
• Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan.

  2021cites this paper
• Complement Activation in the Central Nervous System: A Biophysical Model for Immune Dysregulation in the Disease State

  2021cites this paper
• Novel host defence mechanisms during bacterial infections

  2020cites this paper
• Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort

  2020cites this paper
• Astrocyte-derived extracellular vesicles: Neuroreparative properties and role in the pathogenesis of neurodegenerative disorders.

  2020cites this paper
• Methylene blue and its importance in medicine

  2020cites this paper
• Complement C6 deficiency exacerbates pathophysiology after spinal cord injury

  2020cites this paper
• Soluble Membrane Attack Complex: Biochemistry and Immunobiology

  2020cites this paper
• Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer’s Disease

  2020cites this paper
• Amyloid-beta peptide neurotoxicity in human neuronal cells is associated with modulation of insulin-like growth factor transport, lysosomal machinery and extracellular matrix receptor interactions

  2020cites this paper
• ApoE4: an emerging therapeutic target for Alzheimer’s disease

  2019cites this paper
• Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review

  2019cites this paper
• Somatic mutation that affects transcription factor binding upstream of CD55 in the temporal cortex of a late-onset Alzheimer disease patient

  2019cites this paper
• Toxoplasmosis: A pathway to neuropsychiatric disorders

  2019cites this paper
• Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer’s Disease Pathogenesis in a Transgenic Mouse Model

  2019cites this paper
• Complement pathway in Alzheimer’s pathology and retinal neurodegenerative disorders – the road ahead

  2019cites this paper
• Molecular Mechanisms of Synaptotoxicity and Neuroinflammation in Alzheimer’s Disease

  2018cites this paper
• The genetic landscape of Alzheimer disease.

  2018cites this paper
• 18 Immune Dysfunction in Autism Spectrum Disorder

  2018cites this paper
• Deep Profiling of the Aggregated Proteome in Alzheimer’s Disease: From Pathology to Disease Mechanisms

  2018cites this paper
• Common molecular biomarker signatures in blood and brain of Alzheimer’s disease

  2018cites this paper
• Novelties in the field of autoimmunity - 1st Saint Petersburg congress of autoimmunity, the bridge between east and west.

  2017cites this paper
• Complement system biomarkers in first episode psychosis

  2017cites this paper
• Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis.

  2017cites this paper
• Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm).

  2017cites this paper
• Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer’s Disease Pathology in Older Adults

  2017cites this paper
• Neuroinflammatory genes associated with post-traumatic stress disorder: implications for comorbidity

  2017cites this paper
• Effects of Anti-viral Acute Phase Response on Hippocampal Glutamate Regulation

  2016cites this paper
• The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease.

  2015cites this paper
• Allergy and Alzheimer disease

  2015cites this paper
• Genetics ignite focus on microglial inflammation in Alzheimer’s disease

  2015cites this paper
• Funktionelle Charakterisierung von Age-Related Maculopathy Susceptibility 2 - ARMS2

  2015cites this paper
• Uncovering the Path to Neurodegeneration from Playingfield to Battlefield

  2014cites this paper
• Peptide therapeutics in neurodegenerative disorders.

  2014cites this paper
• CR1 in Alzheimer's Disease

  2014cites this paper
• Novel Role of Mannose Binding Lectin in Neuroinflammation and Neurocognitive Consequences in HIV-1 Infected Brain /

  2014cites this paper
• Atlas of Genetics and Cytogenetics in Oncology and Haematology CLDN 9 ( claudin 9 )

  2013cites this paper
• Expression and Role of Anaphylatoxin Receptors on Human Colonic Epithelial Cells

  2013cites this paper
• Blood Plasma IgG Fc Glycans are Significantly Altered in Alzheimer's Disease and Progressive Mild Cognitive Impairment

  2013cites this paper
• CD59 (CD59 molecule, complement regulatory protein)

  2013cites this paper
• What does complement do in Alzheimer’s disease? Old molecules with new insights

  2013cites this paper
• Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies.

  2013cites this paper
• A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer's disease in the ADNI cohort

  2012cites this paper
• Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease?

  2012cites this paper
• The critical role of adrenomedullin and its binding protein, AMBP-1, in neuroprotection

  2012cites this paper
• Resveratrol, a neuroprotective supplement for Alzheimer's disease.

  2012cites this paper
• Immune Dysfunction in Autism Spectrum Disorder

  2011cites this paper
• Characterisation of different nanoparticles with a potential use for drug delivery in neuropsychiatric disorders

  2011cites this paper
• Rôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer

  2010cites this paper
• Systems Biology and the Discovery of Diagnostic Biomarkers

  2010cites this paper
• Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease.

  2010cites this paper
• Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration

  2010cites this paper
• Inflammation: good or bad for ADHD?

  2010cites this paper
• Microglia and inflammation in Alzheimer's disease.

  2010cites this paper
• The complement system

  2010influential citation
• Neuronal death in Alzheimer’s disease and therapeutic opportunities

  2009cites this paper
• Anesthesia-mediated neuroin fl ammatory sequelae in post operative cognitive dysfunction: mechanisms and therapeutic implications

  year unknowncites this paper